

POSTER PRESENTATION

Open Access

PReS-FINAL-2077: Lung function evaluation in a juvenile idiopathic arthritis cohort

I Machado Vaz¹, M Rodrigues^{2*}, I Azevedo³, J Winck⁴, I Brito⁵

From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia. 25-29 September 2013

Introduction

Juvenile idiopathic arthritis (JIA) is the most common rheumatologic disorder of childhood. It is a group of diseases characterized by chronic synovitis, associated with many extra-articular manifestations including pulmonary involvement, usually in the systemic type.

Alterations of pulmonary function in JIA may be a complication of the underlying disease or related to treatment with methotrexate.

Numerous reports have documented the association of rheumatoid arthritis and pulmonary abnormalities. Also, methotrexate may cause severe adverse pulmonary sideeffects in adults with rheumatoid arthritis.

While respiratory function in adults with rheumatoid arthritis has been extensively investigated, few studies have been carried out in JIA children.

Objectives

To evaluate lung function in a cohort of Juvenile Idiopathic Arthritis (JIA) patients followed in a tertiary care center

Methods

Transversal study of consecutive JIA patients recruited in a Pediatric Rheumatology Clinic, between December 2011 and March 2012. Clinical history and past medical history were collected by using medical records and a structured questionnaire. Lung function evaluation included spirometry, carbon monoxide diffusing capacity (DLCO) and sniff nasal inspiratory pressure (SNIF). Laboratory workup included complete blood count, ESR, CRP, ANA and RF.

Results

41 recruited patients had ages between 6 and 20 years (average 11.8 \pm 4.1), 23 (62.2%) were females. 4 were lost to follow-up.

2 patients had weight <P5 and 2 with weight >P95, 1 had height <P5 and 5 with height >P95, the remaining had adequate growth.

Disease duration was 62.4 ± 29.1 months from diagnosis. 17 (45.9%) had oligoarticular, 8 (21.6%) systemic and 6 (16.2%) polyarticular type.

31(83.3%) had no active synovitis, and only 2 (5.7%) had 3 or more active joints. 60% patients were currently on medication: 10 (28.6%) methotrexate, 3 (8.6%) sulfasalazine, 1 (2.9%) anti-TNF, 1 (2.9%) anti-IL1 and 2 (5.7%) methotrexate plus anti-TNF.

No patients had previous known lung disease or respiratory symptoms. Lung function tests were mostly normal: Forced Vital Capacity (FVC%) 97.9 \pm 17.0, Forced Expiratory Volume in 1 second (FEV1%) 104.2 \pm 17.5, FEV1/FVC% 99.18 \pm 12.2, Total Lung Capacity (TLC%) 94.6 \pm 14.5, Residual Volume (RV%) 130.5 \pm 53.1, DLCO% 93.1 \pm 14,2, SNIF 69.6 \pm 26.5. Only 3 patients had lung function changes - 2 restrictive and 1 obstructive spirometry patterns, no patients had changes in DLCO.

Conclusion

The low prevalence of lung function changes in our cohort is in agreement with the literature. In contrast to studies performed in adult rheumatoid arthritis patients, in children with juvenile idiopathic arthritis impairment of lung function seems to be a rare event.

The small sample size, the fact that most of the patients were in remission, as well as the lack of a control group can contribute to the difficulty in interpreting the results.

²Pediatrics, São João Hospital, Porto, Portugal Full list of author information is available at the end of the article



Prospective follow-up of this cohort, particularly those with lung function changes, will be paramount.

Disclosure of interest

None declared.

Authors' details

¹Physical Medicine and Rehabilitation Department, São João Hospital, Porto, Portugal. ²Pediatrics, São João Hospital, Porto, Portugal. ³Pediatric Pulmonology Unit, São João Hospital, Porto, Portugal. ⁴Pulmonology, São João Hospital, Porto, Portugal. ⁵Pediatric Rheumatology Unit, São João Hospital, Porto, Portugal.

Published: 5 December 2013

doi:10.1186/1546-0096-11-S2-P89

Cite this article as: Machado Vaz et al.: PReS-FINAL-2077: Lung function evaluation in a juvenile idiopathic arthritis cohort. Pediatric Rheumatology 2013 11(Suppl 2):P89.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

